ArticleVox sanguinis2025
A procedure using low-cost reagents to prepare allogeneic platelet gel from standard platelet units.
Article in Vox sanguinis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A procedure using low-cost reagents to prepare allogeneic platelet gel from standard platelet units.Vox sanguinis · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesHighly effective procedures for the preparation of allogeneic platelet gel (PG) use Ca-gluconate and batroxobin, an expensive commercial reagent. In this preliminary study, we explored the use of the plasmin-inhibitor, low-cost drug tranexamic acid (TXA) in place of batroxobin, based on the literature supporting TXA ability to prevent fibrinolysis and stabilize the gel formed by fibrin polymerization prompted by Ca-gluconate. MATERIALS AND
methodsEight blood centres determined PG weight and volume of non-gelled, liquid portion in 116 PG prepared in 20-mL commercial BioNest D bags. Ten-millilitre platelet aliquots from platelets in 100% plasma or in 35% plasma/65% platelet additive solution (PAS) were aseptically transferred into the D bag, followed by the injection of 3.3 mL of 10% Ca-gluconate and 0.4 mL of TXA. After 30-min incubation, PG weight and non-gelled liquid volume were determined.
resultsPG weight and liquid volume at 30 min were 6.5 ± 3.4 g and 7.4 ± 3.5 mL with platelets in 100% plasma, and 3.7 ± 3.0 g and 10.2 ± 3.3 mL with PAS platelets, respectively.
conclusionThis study provides preliminary evidence supporting the use of TXA as a low-cost reagent for PG manufacturing from platelets in 100% plasma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.